NewsNovo
The case for tadalafil has long been clear: proven efficacy for erectile dysfunction and enlarged prostate symptoms, backed by decades of clinical use.
A study now published in the British Journal of Ophthalmology, covering nearly 74,000 men, complicates that picture.
Men who took the drug were 22% more likely to develop glaucoma than those who did not, surfacing a visual risk that patients rarely associate with the medication.
An international research team compared roughly 37,000 men prescribed tadalafil against a matched group not using phosphodiesterase type 5 inhibitors, the drug class that includes Eli Lilly's Cialis, following both cohorts for up to five years.
Keep reading